NxGen MDx announces the move of their Non-Invasive Prenatal Test in-house

Grand Rapids, MI, December 2, 2016 – NxGen MDx announced today that it brought its NxGen Informed Prenatal Test in-house.

“By bringing the test in house, we’ve been able to improve customer service through shortened turnaround times and at the same time keep costs down for patients,” says Alan Mack, CEO of NxGen MDx.

A decrease in turnaround times by 25% combined with an increase in test volume has led to more job opportunities at the Grand Rapid headquarters.

The NxGen Informed Prenatal Test uses the illumina NGS platform and can, with the highest degree of accuracy, determine the presence of chromosomal aneuploidies in a developing fetus. The test can be done as early as 10 weeks into the pregnancy and has no limitations in terms of ethnicity, body mass index, assisted reproductive technology, or egg donor cases.

Patients can use the information this test provides to learn more about the risk of non-inherited chromosomal conditions and weigh the benefits and risks of further invasive diagnostic procedures.

About NxGen MDx
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGen MDx’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan.

The Right Place assists molecular research lab with expansion in Grand Rapids, Michigan

NxGen MDx to invest $2.8 million, creating 37 new high-tech jobs

GRAND RAPIDS, MICH. (12/14/16) – Regional economic development organization The Right Place, Inc., along with its local and state partners in the City of Grand Rapids, today announced the approval of a Michigan Strategic Fund (MSF) incentive that will bring 37 new high-tech, life science jobs and $2.8 million in new investment to Grand Rapids, Michigan over the next three years.

Grand Rapids-based NxGen MDx plans to expand at its current location, 801 Broadway Ave NW Suite 203, Grand Rapids, MI 49504. The new expansion will increase the laboratory’s testing capacity and respond to increased customer demand expected to reach 300 percent over last year.

“We chose to launch NxGen in Grand Rapids back in 2014 within its prestigious medical corridor to offer our patients the very best and brightest of the genetics field,” said Kristin Sherman, Chief Financial Officer, NxGen MDx. “The expert support provided by The Right Place, combined with the collaborative resources of Grand Rapids’ Medical Mile, made the decision easy on where the next chapter of our growth would take place.”

NxGen MDx is a women’s health care organization that offers genetic screening so patients can plan their reproductive journey. NxGen offers a variety of genetic screens for inherited diseases such as Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome. NxGen also provides best in class genetics counselors and customer service to ensure patients can easily understand their results. For more information on genetic screening and what Genetic screens NxGen offers visit www.nxgenmdx.com.

“Grand Rapids’ life sciences cluster continues to see significant growth, and NxGen is yet the latest example of that growth,” said Eric Icard, Senior Business Development Manager, The Right Place, Inc. “Companies like NxGen are not only great for our community in terms of new jobs, but they also raise national awareness of West Michigan within the industry.”

The business development team at The Right Place worked to ensure NxGen’s expansion occurred in West Michigan over a competing location in Florida. By assembling a cross-functional team of state and local resources, the team was able to work with the MEDC and City of Grand Rapids to build an aggressive business retention/expansion incentive package.

The City of Grand Rapids is supportive of NxGen’s decision to expand in the city, bringing 37 new high-tech jobs to the community. The city is considering the approval of a local PA 328 Property Tax Abatement to provide support for NxGen’s capital investment.

“This project is exciting growth for a graduate of the Grand Rapids SmartZone life science incubator. NxGen MDx began as a tenant, graduated from our incubator in 2014 and has been experiencing growth since making their location decision within the City of Grand Rapids,” said Kara Wood, City of Grand Rapids, Managing Director of Economic Development Services. “The City looks forward to the continued success of this company, as they provide good paying jobs for local talent and support the growth of Grand Rapids’ life science industry cluster.”

West Michigan’s Life Science Cluster Growth
With over $2 billion of investments along Grand Rapids’ Medical Mile and life sciences corridor, West Michigan has reached a critical mass that has made the region a destination for breakthrough healthcare, research, and medical device development and manufacturing. The industry now employs over 57,000 in the 13-county region with average earnings of nearly $65,000 per year.

West Michigan’s life sciences industry has experienced 25.9 percent employment growth over the past 10 years, compared to the national average of 15.7 percent.

About The Right Place, Inc.
The Right Place, Inc., is a regional non-profit economic development organization founded in 1985 and supported through investments from the private and public sector. Its mission is to promote economic growth in the areas of quality employment, productivity and technology in West Michigan by developing jobs through leading business retention, expansion and attraction efforts. For more information, visit: www.rightplace.org

About NxGen MDx
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGEN MDx’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGEN MDx is located in Grand Rapids, Michigan.

Two Midwest Companies Join Forces to Speed Development of Test to Identify Women at Risk for Preterm Birth

In a collaborative move to expand their diagnostic screening and testing portfolios, NxGen MDx, LLC., and NX Prenatal, Inc., announced a joint partnership to speed the development and deployment of a blood test to detect pregnancy biomarkers of preterm birth.

The partnership brings together NX Prenatal’s experience in developing exosome-associated biomarkers from maternal blood with NxGEN MDx’s comprehensive genetic screening solutions for women’s health applications.

Preterm birth affects 1 in 8 U.S. women and accounts for nearly half a million preterm births each year, costing families and insurers an estimated $26 billion. Globally, there are approximately 15 million preterm births annually, accounting for 75% of perinatal deaths. Preterm births are also a major cause of short and long-term medical complications in infants and children.

“We are excited to partner with the innovative NX Prenatal team. Our combined efforts are designed to identify which pregnant women are at risk for delivering prematurely as early as possible. NX Prenatal’s proven technology uniquely holds the potential to achieve this breakthrough,” says Alan Mack, CEO of NxGEN MDx.

Brian Brohman, Co-CEO of Nx Prenatal, concurs. “Our proprietary NeXosome Platform has the potential to identify women at risk for preterm birth as early as 10 weeks gestation — dramatically reducing the 22 weeks of current tests.”

“Clearly, our partnership aligns with our respective corporate missions. NX Prenatal’s new generation of diagnostics complements our current suite of tests that can help families and their physicians plan for healthy pregnancy outcomes,” adds Mack.

Identifying risk for preterm births earlier has a powerful ripple effect as well. “In addition to helping clinicians proactively manage those at greatest risk, patients and families will benefit from personalized care and potential tailored interventions, while payers and self-insured employers may ultimately enjoy lower claims costs related to preterm birth,” notes Gail Page, Executive Chair of NX Prenatal.

Financial terms of the transaction were not disclosed.

About NX Prenatal Inc.
NX Prenatal Inc. is a private U.S. based molecular diagnostics company located in Louisville, KY. NX Prenatal is developing diagnostic assays for adverse pregnancy outcomes and conditions such as preterm birth. The company has unlocked a new library of biomarkers for prenatal risk assessment as early as 10 weeks gestation. For more information, visit the company’s website at www.nxprenatal.com.

About NxGen MDx
NxGen MDx LLC is a leading clinical molecular diagnostics laboratory delivering highly accurate and precise genetic screening to detect genetic diseases or abnormalities to help guide family planning decisions for couples and their healthcare providers. Unlike other laboratories, NxGEN MDx’s technology examines the entire gene rather than parts of the gene, giving families a comprehensive assessment of their true risk. NxGen MDx is located in Grand Rapids, Michigan.